#None #Menarini Group #Bofanglutide #Gan & Lee

Gan & Lee and Menarini Group Collaborate on Bofanglutide Development

In a significant strategic partnership, Gan & Lee Pharmaceuticals has announced an exclusive licensing agreement with the Menarini Group, a leading international bio-pharmaceutical firm based in Florence, Italy. This collaboration is centered on the development and commercialization of Bofanglutide (development code GZR18), a treatment aimed at adults struggling with obesity or overweight. The medication's unique dosing regimen allows for administration once every two weeks, offering a compelling alternative to existing therapies.

Partnership Overview

Under the terms of the agreement, Gan & Lee is set to receive an upfront payment of €62 million, milestone payments that could reach up to €664 million, alongside double-digit royalties on net sales within the licensed territory. The total potential value of this collaboration could amount to approximately €726 million, excluding royalties. Menarini will manage the regulatory submissions and commercialization process across a region encompassing 39 countries, including all 27 EU member states, the UK, Switzerland, Norway, Iceland, Liechtenstein, and several Balkan nations.

Targeting Metabolic Diseases

This partnership marks a crucial advancement for Menarini, as it seeks to expand its presence in the metabolic disease sector—a field where there is an increasing patient population requiring effective treatment options. Bofanglutide has shown promising results in tackling obesity and is classified as a GLP-1 receptor agonist, a class of drugs known for their efficacy in weight management.

Clinical Development and Efficacy

Both Phase II and pivotal Phase III trials in China, as well as studies conducted in the United States, have demonstrated Bofanglutide's effectiveness in weight reduction and tolerance, consistent with the profiles of other GLP-1 therapies. The drug’s once-every-two-weeks injection schedule represents a 50% reduction in administration frequency compared to weekly GLP-1 agonists, which could enhance patient compliance and treatment outcomes.

Dr. Wei Chen, CEO of Gan & Lee, expressed excitement about this partnership, emphasizing that it represents a pivotal step in introducing Bofanglutide to the European market. He stated that this collaboration merges Gan & Lee’s extensive experience in clinical development and manufacturing with Menarini's regulatory and commercialization expertise, aiming to provide therapeutic options for millions of individuals grappling with obesity or overweight conditions.

Future Directions

Looking ahead, Gan & Lee plans to kickstart an international Phase III clinical trial program to support Bofanglutide's registration in Europe and other highly regulated markets. This commitment to innovation and high-quality product development reflects Gan & Lee's vision to broaden its global footprint in the therapeutic landscape for diabetes and obesity treatment. Through this deal, Gan & Lee aims not only to strengthen its position in the competitive biopharmaceutical industry but also to enhance patient accessibility to Bofanglutide.

Menarini's CEO, Elcin Barker Ergun, remarked on the encouraging clinical data surrounding Bofanglutide, highlighting its potential to offer metabolic benefits beyond weight loss. She stressed the significance of the bi-weekly dosing schedule, which may set the treatment apart from existing alternatives. The partnership, thus, not only fuels the development pipeline of both firms but also stands to influence how metabolic diseases are managed in the healthcare system.

Conclusion

This exclusive licensing agreement embodies a strategic milestone for both Gan & Lee and Menarini Group as they endeavor to address the growing challenge of metabolic disorders. With Gan & Lee's innovative products and Menarini's extensive market reach and regulatory knowledge, this collaboration is primed to elevate Bofanglutide's profile in Europe, providing a much-needed therapeutic option for those in need. As the collaboration unfolds, both companies remain committed to delivering on the promise of this novel therapy, demonstrating the transformative potential of strategic partnerships in advancing healthcare solutions.

For more information, you can visit the respective company websites: Gan & Lee Pharmaceuticals and Menarini Group.